Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914703963> ?p ?o ?g. }
- W2914703963 endingPage "993" @default.
- W2914703963 startingPage "979" @default.
- W2914703963 abstract "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with highly aggressive behavior and early systemic metastasis. The survival rates for osteosarcoma remain unchanged over the past two decades. Studies aiming to find new or alternative therapies for patients with refractory osteosarcoma are urgently needed. Anlotinib, a novel multi-targeted tyrosine kinase inhibitor (TKI), has exhibited encouraging clinical activity in NSLCC and soft tissue sarcoma, whereas its effect on osteosarcoma has not been studied. In our study, we investigated the anti-tumor activity and underlying mechanism of anlotinib in osteosarcoma. Various in vitro and in vivo models of human osteosarcoma were used to determine the anti-proliferative, anti-angiogenesis and anti-metastasis efficacy of anlotinib. Our results showed that anlotinib suppressed tumor growth and increased the chemo-sensitivity of osteosarcoma. In addition, anlotinib inhibited migration and invasion in osteosarcoma cells. Furthermore, in order to explore the anti-tumor mechanism of anlotinib, phospho-RTK antibody arrays were performed. These analyses confirmed that anlotinib suppressed the phosphorylation of MET, VEGFR2 and the downstream signaling pathway activation. Moreover, we demonstrated that anlotinib blocked hepatocyte growth factor (HGF)-induced cell migration, invasion and VEGF-induced angiogenesis. Notably, a 143B-Luc orthotopic osteosarcoma model further showed that anlotinib significantly inhibited growth and lung metastasis of implanted tumor cells. Our preclinical work indicates that anlotinib acts as a novel inhibitor of VEGFR2 and MET that blocks tumorigenesis in osteosarcoma, which could be translated into future clinical trials." @default.
- W2914703963 created "2019-02-21" @default.
- W2914703963 creator A5005135027 @default.
- W2914703963 creator A5010301775 @default.
- W2914703963 creator A5023480337 @default.
- W2914703963 creator A5023751554 @default.
- W2914703963 creator A5029915324 @default.
- W2914703963 creator A5029967798 @default.
- W2914703963 creator A5030030338 @default.
- W2914703963 creator A5031953394 @default.
- W2914703963 creator A5033210505 @default.
- W2914703963 creator A5034013523 @default.
- W2914703963 creator A5035701638 @default.
- W2914703963 creator A5039499293 @default.
- W2914703963 creator A5048069511 @default.
- W2914703963 creator A5055817420 @default.
- W2914703963 creator A5063170943 @default.
- W2914703963 creator A5065599307 @default.
- W2914703963 creator A5072285989 @default.
- W2914703963 creator A5074391954 @default.
- W2914703963 creator A5085233592 @default.
- W2914703963 date "2019-02-15" @default.
- W2914703963 modified "2023-10-17" @default.
- W2914703963 title "Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis <i>via</i> dual blockade of VEGFR2 and MET in osteosarcoma" @default.
- W2914703963 cites W1967600348 @default.
- W2914703963 cites W1974228208 @default.
- W2914703963 cites W1977999028 @default.
- W2914703963 cites W1992018116 @default.
- W2914703963 cites W2011551652 @default.
- W2914703963 cites W2013881151 @default.
- W2914703963 cites W2024585236 @default.
- W2914703963 cites W2033878783 @default.
- W2914703963 cites W2034633555 @default.
- W2914703963 cites W2038927253 @default.
- W2914703963 cites W2039013742 @default.
- W2914703963 cites W2055191970 @default.
- W2914703963 cites W2061487132 @default.
- W2914703963 cites W2069421644 @default.
- W2914703963 cites W2077462602 @default.
- W2914703963 cites W2091774189 @default.
- W2914703963 cites W2093538839 @default.
- W2914703963 cites W2093921289 @default.
- W2914703963 cites W2103875073 @default.
- W2914703963 cites W2105968397 @default.
- W2914703963 cites W2106688644 @default.
- W2914703963 cites W2122390343 @default.
- W2914703963 cites W2123745849 @default.
- W2914703963 cites W2133664541 @default.
- W2914703963 cites W2140088548 @default.
- W2914703963 cites W2153871090 @default.
- W2914703963 cites W2157539187 @default.
- W2914703963 cites W2180238811 @default.
- W2914703963 cites W2342822806 @default.
- W2914703963 cites W2511218030 @default.
- W2914703963 cites W2520896452 @default.
- W2914703963 cites W2528424364 @default.
- W2914703963 cites W2530995753 @default.
- W2914703963 cites W2577284382 @default.
- W2914703963 cites W2578095037 @default.
- W2914703963 cites W2586959389 @default.
- W2914703963 cites W2602981376 @default.
- W2914703963 cites W2731227355 @default.
- W2914703963 cites W2743762419 @default.
- W2914703963 cites W2744886175 @default.
- W2914703963 cites W2767025366 @default.
- W2914703963 cites W2791602004 @default.
- W2914703963 cites W2795758525 @default.
- W2914703963 cites W2889570909 @default.
- W2914703963 cites W2902669105 @default.
- W2914703963 cites W4229617316 @default.
- W2914703963 cites W4241813594 @default.
- W2914703963 doi "https://doi.org/10.1002/ijc.32180" @default.
- W2914703963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30719715" @default.
- W2914703963 hasPublicationYear "2019" @default.
- W2914703963 type Work @default.
- W2914703963 sameAs 2914703963 @default.
- W2914703963 citedByCount "79" @default.
- W2914703963 countsByYear W29147039632019 @default.
- W2914703963 countsByYear W29147039632020 @default.
- W2914703963 countsByYear W29147039632021 @default.
- W2914703963 countsByYear W29147039632022 @default.
- W2914703963 countsByYear W29147039632023 @default.
- W2914703963 crossrefType "journal-article" @default.
- W2914703963 hasAuthorship W2914703963A5005135027 @default.
- W2914703963 hasAuthorship W2914703963A5010301775 @default.
- W2914703963 hasAuthorship W2914703963A5023480337 @default.
- W2914703963 hasAuthorship W2914703963A5023751554 @default.
- W2914703963 hasAuthorship W2914703963A5029915324 @default.
- W2914703963 hasAuthorship W2914703963A5029967798 @default.
- W2914703963 hasAuthorship W2914703963A5030030338 @default.
- W2914703963 hasAuthorship W2914703963A5031953394 @default.
- W2914703963 hasAuthorship W2914703963A5033210505 @default.
- W2914703963 hasAuthorship W2914703963A5034013523 @default.
- W2914703963 hasAuthorship W2914703963A5035701638 @default.
- W2914703963 hasAuthorship W2914703963A5039499293 @default.
- W2914703963 hasAuthorship W2914703963A5048069511 @default.
- W2914703963 hasAuthorship W2914703963A5055817420 @default.
- W2914703963 hasAuthorship W2914703963A5063170943 @default.